Performance status, survival, and end-of-life care in adults with non-small cell lung cancer (NSCLC) treated with immunotherapy

MLA

Morgan Rl Lichtenstein, et al. “Performance Status, Survival, and End-of-Life Care in Adults with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy.” Journal of Clinical Oncology, vol. 37, Nov. 2019, p. 49. EBSCOhost, https://doi.org/10.1200/jco.2019.37.31_suppl.49.

APA

Morgan Rl Lichtenstein, Ryan D. Nipp, Joseph A. Greer, Laura A. Petrillo, Justin F. Gainor, Jennifer S. Temel, Kerry L. Reynolds, & Areej El-Jawahri. (2019). Performance status, survival, and end-of-life care in adults with non-small cell lung cancer (NSCLC) treated with immunotherapy. Journal of Clinical Oncology, 37, 49. https://doi.org/10.1200/jco.2019.37.31_suppl.49

Chicago

Morgan Rl Lichtenstein, Ryan D. Nipp, Joseph A. Greer, Laura A. Petrillo, Justin F. Gainor, Jennifer S. Temel, Kerry L. Reynolds, and Areej El-Jawahri. 2019. “Performance Status, Survival, and End-of-Life Care in Adults with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy.” Journal of Clinical Oncology 37 (November): 49. doi:10.1200/jco.2019.37.31_suppl.49.